Research
Hormonal
Treatment with the PPAR-gamma agonist rosiglitazone increases mitochondrial density and alters mitochondrial morphology (shorter, denser profiles with lamellar cristae) in differentiated white adipocytes.
Rosiglitazone, a PPAR-gamma agonist, increases mitochondrial density and changes their structure in fat cells. This cellular remodeling may contribute to the drug's ability to improve insulin sensitivity, although its clinical use is limited by safety profiles.
GoodSupportsHIGH confidence
treatment of 3T3-L1 adipocytes with rosiglitazone... led to a further increase in mitochondrial density and to qualitative changes in mitochondrial structure
Why this rating
Robust in vitro evidence with morphological and biochemical confirmation.
Source
Mitochondrial Biogenesis and Remodeling during Adipogenesis and in Response to the Insulin Sensitizer Rosiglitazone
Leanne Wilson-Fritch et al. · Molecular and Cellular Biology · 2003
DOI 10.1128/mcb.23.3.1085-1094.2003
mechanism_onlyCited 462×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →